{"id":"low-titer-anti-influenza-plasma","safety":{"commonSideEffects":[{"rate":null,"effect":"Transfusion-related acute lung injury (TRALI)"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Volume overload"},{"rate":null,"effect":"Transfusion-transmitted infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This convalescent plasma product contains low concentrations of anti-influenza antibodies harvested from donors who have recovered from influenza infection. When transfused into acutely infected patients, these antibodies bind to viral surface antigens and facilitate viral neutralization and clearance. The approach leverages passive immunity to reduce viral load and potentially ameliorate disease severity in hospitalized influenza patients.","oneSentence":"Low-titer anti-influenza plasma provides passive immunotherapy by transferring antibodies from donors with prior influenza exposure to neutralize circulating influenza virus in infected patients.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:38.319Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hospitalized patients with acute influenza infection"}]},"trialDetails":[{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT02572817","phase":"PHASE3","title":"Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-11","conditions":"Influenza A Virus Infection","enrollment":138}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Low-titer anti-influenza plasma","genericName":"Low-titer anti-influenza plasma","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Biologic","firstApprovalDate":"","aiSummary":"Low-titer anti-influenza plasma provides passive immunotherapy by transferring antibodies from donors with prior influenza exposure to neutralize circulating influenza virus in infected patients. Used for Hospitalized patients with acute influenza infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}